Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1952 1
1954 1
1955 1
1956 1
1958 1
1959 1
1962 2
1963 3
1964 2
1966 1
1967 2
1968 7
1969 15
1970 9
1971 6
1972 13
1973 17
1974 22
1975 25
1976 19
1977 26
1978 13
1979 15
1980 28
1981 20
1982 27
1983 24
1984 38
1985 48
1986 29
1987 32
1988 41
1989 45
1990 63
1991 74
1992 67
1993 90
1994 82
1995 111
1996 137
1997 117
1998 174
1999 206
2000 197
2001 239
2002 311
2003 356
2004 490
2005 578
2006 587
2007 695
2008 745
2009 801
2010 820
2011 977
2012 963
2013 1050
2014 1129
2015 1050
2016 1046
2017 1097
2018 1070
2019 1030
2020 1066
2021 962
2022 786
2023 741
2024 823
2025 889
2026 586

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,866 results

Results by year

Filters applied: . Clear all
Page 1
Tapering biologic DMARDs in rheumatoid arthritis.
Braverman G, Bridges SL, Moreland LW. Braverman G, et al. Curr Opin Pharmacol. 2022 Dec;67:102308. doi: 10.1016/j.coph.2022.102308. Epub 2022 Oct 21. Curr Opin Pharmacol. 2022. PMID: 36274358 Review.
With the arrival of biologics and the shift toward treat-to-target therapy, the possibility of a sustained clinical response has become an achievable goal for many patients with rheumatoid arthritis (RA). ...This article will (1) summarize the current evidenc …
With the arrival of biologics and the shift toward treat-to-target therapy, the possibility of a sustained clinical response has beco …
Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?
Bastida C, Ruíz V, Pascal M, Yagüe J, Sanmartí R, Soy D. Bastida C, et al. Br J Clin Pharmacol. 2017 May;83(5):962-975. doi: 10.1111/bcp.13192. Epub 2017 Jan 18. Br J Clin Pharmacol. 2017. PMID: 27990682 Free PMC article. Review.
The use of biologics has significantly changed the management of rheumatoid arthritis over the last decade, becoming the cornerstone treatment for many patients. ...In general, dose individualization for biologics should be implemented increasingly in …
The use of biologics has significantly changed the management of rheumatoid arthritis over the last decade, becoming th …
Biologic therapies and bone loss in rheumatoid arthritis.
Zerbini CAF, Clark P, Mendez-Sanchez L, Pereira RMR, Messina OD, Uña CR, Adachi JD, Lems WF, Cooper C, Lane NE; IOF Chronic Inflammation and Bone Structure (CIBS) Working Group. Zerbini CAF, et al. Osteoporos Int. 2017 Feb;28(2):429-446. doi: 10.1007/s00198-016-3769-2. Epub 2016 Oct 31. Osteoporos Int. 2017. PMID: 27796445 Review.
INTRODUCTION: Rheumatoid arthritis (RA) is a common systemic autoimmune disease of unknown cause, characterized by a chronic, symmetric, and progressive inflammatory polyarthritis. ...Only three epidemiological studies analyzed the effect on fractures after anti-TNF …
INTRODUCTION: Rheumatoid arthritis (RA) is a common systemic autoimmune disease of unknown cause, characterized by a chronic, …
Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review.
Martín-López M, Carmona L, Balsa A, Calvo-Alén J, Sanmartí R, Tornero J, Rosas J. Martín-López M, et al. Rheumatol Int. 2018 Jun;38(6):975-983. doi: 10.1007/s00296-018-4022-4. Epub 2018 Apr 3. Rheumatol Int. 2018. PMID: 29616303
The utility of monitoring drug levels in rheumatoid arthritis and spondyloarthritis patients on biological therapy is called into question. ...Studies were small and with limitations, but suggest that measurement drug levels may be useful in patients in remis …
The utility of monitoring drug levels in rheumatoid arthritis and spondyloarthritis patients on biological therapy is c …
Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives.
Chan SJ, Stamp LK, Liebergreen N, Ndukwe H, Marra C, Treharne GJ. Chan SJ, et al. Patient. 2020 Apr;13(2):225-234. doi: 10.1007/s40271-019-00403-9. Patient. 2020. PMID: 31802391
BACKGROUND AND OBJECTIVE: Biologic therapies are cost effective for active rheumatoid arthritis but have adverse effects and are costly. ...METHODS: Patients with rheumatoid arthritis with diverse experiences of biologics with different m …
BACKGROUND AND OBJECTIVE: Biologic therapies are cost effective for active rheumatoid arthritis but have adverse effect …
The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis.
Favalli EG, Pregnolato F, Biggioggero M, Meroni PL. Favalli EG, et al. Semin Arthritis Rheum. 2014 Jun;43(6):730-7. doi: 10.1016/j.semarthrit.2013.11.006. Epub 2013 Nov 13. Semin Arthritis Rheum. 2014. PMID: 24332807
OBJECTIVES: To indirectly compare the 12-month effects of available biologic agents in slowing RA radiographic progression. METHODS: A systematic review of literature of randomised, double-blind, controlled trials (RCTs) evaluating RA radiographic progression as end …
OBJECTIVES: To indirectly compare the 12-month effects of available biologic agents in slowing RA radiographic progression. ME …
Clinical application of biological agents in rheumatoid arthritis.
Cheng L, Rong X. Cheng L, et al. Transpl Immunol. 2025 Mar;89:102187. doi: 10.1016/j.trim.2025.102187. Epub 2025 Jan 30. Transpl Immunol. 2025. PMID: 39892767 Free article. Review.
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder primarily distinguished by synovial inflammation, which, as the disease evolves, can lead to bone erosion and destruction. ...Given these challenges, the identification of targeted therapies to man …
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder primarily distinguished by synovial inflammation, which, …
The perioperative use of biologic agents in patients with rheumatoid arthritis.
Polachek A, Caspi D, Elkayam O. Polachek A, et al. Autoimmun Rev. 2012 Dec;12(2):164-8. doi: 10.1016/j.autrev.2012.04.001. Epub 2012 Apr 12. Autoimmun Rev. 2012. PMID: 22522087 Review.
Biologic drugs have gained an important place in the treatment of rheumatic diseases. These medications may, however, pose a higher risk of infections in rheumatic patients who a priori are prone to infections. The potential consequences of the immunosuppressive effects of …
Biologic drugs have gained an important place in the treatment of rheumatic diseases. These medications may, however, pose a higher r …
Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis.
Cavalli G, Favalli EG. Cavalli G, et al. Expert Rev Clin Immunol. 2019 Dec;15(12):1313-1322. doi: 10.1080/1744666X.2020.1686976. Epub 2019 Nov 10. Expert Rev Clin Immunol. 2019. PMID: 31663390 Review.
Introduction: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease, which affects joints as well as extra-articular tissues. ...Currently, there is a need for management strategies aimed at limiting treatment-related adverse events and costs in good r …
Introduction: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease, which affects joints as well as extra-artic …
Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
Chen DY, Lau CS, Elzorkany B, Hsu PN, Praprotnik S, Vasilescu R, Marshall L, Llamado L. Chen DY, et al. Int J Rheum Dis. 2018 Feb;21(2):362-372. doi: 10.1111/1756-185X.13238. Epub 2017 Dec 4. Int J Rheum Dis. 2018. PMID: 29205904 Review.
AIM: To review the published studies that dose down and then discontinue biologic therapy in patients with rheumatoid arthritis (RA), particularly concerning the criteria for such dosing and the impact on clinical outcomes. METHODS: Published studies conducte …
AIM: To review the published studies that dose down and then discontinue biologic therapy in patients with rheumatoid arthr …
19,866 results
You have reached the last available page of results. Please see the User Guide for more information.